Nurix Launches Collaboration With Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute To Expand Its Drug Discovery Program

SAN FRANCISCO--(BUSINESS WIRE)--Nurix, Inc., a leader in discovering innovative drugs that modulate protein function through the ubiquitin proteasome system (UPS), announced today the initiation of a research collaboration with Frank Sicheri, Ph.D., Senior Investigator at Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute in Toronto, which is one of the world’s leading biomedical research centers. Dr. Sicheri is a pioneer in the elucidation of structure and function of E2 ubiquitin conjugating enzymes, important components of the UPS. His groundbreaking work has included elucidation of the three-dimensional structure of Cdc34a-ubiquitin complex with small molecule inhibitors.

Help employers find you! Check out all the jobs and post your resume.